|By PR Newswire||
|August 18, 2014 04:39 PM EDT||
WASHINGTON, Aug. 18, 2014 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) President & CEO, Laurie Fenton Ambrose praised the National Cancer Institute's (NCI) new trial, launched today, that will focus on the prevention of recurrence in two specific types of lung cancers when they are caught at early stage and surgically removed.
"This trial demonstrates the power of CT screening to open new research windows on critical problems, such as recurrence, that have eluded solutions to date," she said.
Few trials have been conducted on earlier stage lung cancer because so few lung cancer patients have been diagnosed at early stage. With wider availability of low dose CT, this will change.
This trial, the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, will test whether erlotinib and crizotinib, already approved as targeted therapies for EGFR positive and ALK positive types of late stage lung cancer, can effectively block recurrence when those cancers are found at an earlier stage.
Since the EGFR and ALK mutations are found in just 5% to 10% of lung cancers, NCI estimates that the tumors from 6,000 to 8,000 post-surgical patients would have to be tested for the mutations to yield about 600 patients eligible for the trial.
Patients whose resected tumors test positive will be given adjuvant chemotherapy and possibly radiation, and then treated with either erlotinib or crizotinib and followed for five years for recurrence.
"In this new era of CT screening for lung cancer, the number of lung cancers found at early stage will increase dramatically, making trials and new lifesaving breakthroughs like this feasible," Fenton Ambrose said.
Lung Cancer Alliance, www.lungcanceralliance.org, is the leading national organization providing hope for the lung cancer community by offering patient support, national awareness, community outreach, and advocacy to advance research into early detection and treatments for all forms of lung cancer.
For more details on the trial please go to: http://www.cancer.gov/newscenter/newsfromnci/2014/ALCHEMISTlaunchQandA.
SOURCE Lung Cancer Alliance
Aug. 28, 2016 03:15 PM EDT Reads: 3,475
Aug. 28, 2016 03:00 PM EDT Reads: 721
Aug. 28, 2016 01:45 PM EDT Reads: 3,645
Aug. 28, 2016 01:00 PM EDT Reads: 2,409
Aug. 28, 2016 12:15 PM EDT Reads: 834
Aug. 28, 2016 11:45 AM EDT Reads: 666
Aug. 28, 2016 11:30 AM EDT Reads: 1,944
Aug. 28, 2016 11:00 AM EDT Reads: 3,115
Aug. 28, 2016 11:00 AM EDT Reads: 674
Aug. 28, 2016 10:45 AM EDT Reads: 839
Aug. 28, 2016 10:30 AM EDT Reads: 882
Aug. 28, 2016 10:30 AM EDT Reads: 4,019
Aug. 28, 2016 09:30 AM EDT Reads: 764
Aug. 28, 2016 09:30 AM EDT Reads: 718
Aug. 28, 2016 07:30 AM EDT Reads: 787